Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03275285 · ClinicalTrials.gov registry record · Phase 3
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 302
- Enrollment target
NCT03275285 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 302 participants.
The verdict
NCT03275285, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 302 participants
- Enrollment target
Study Summary
The purpose of this study it to compare the efficacity of isatuximab when combined to carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with multiple myeloma already treated with 1 to 3 prior lines of therapy.
Interventions
- DRUG dexamethasone
- DRUG carfilzomib
- DRUG isatuximab SAR650984
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2017-10-25 |
| Est. Completion | 2025-01-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03275285
The ClinicalTrials.gov registry entry for NCT03275285 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 302 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which dexamethasone is the first listed.
NCT03275285 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03275285 about?
NCT03275285 is a clinical study titled "Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients". The purpose of this study it to compare the efficacity of isatuximab when combined to carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with multiple myeloma already treated with 1 to 3 prior lines of therapy.
What is the current status of trial NCT03275285?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 302 participants. The study started on 2017-10-25. Estimated completion is 2025-01-03.
What interventions are being tested in trial NCT03275285?
The interventions under investigation include: dexamethasone (DRUG), carfilzomib (DRUG), isatuximab SAR650984 (DRUG).
Who is sponsoring clinical trial NCT03275285?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.